Jazz Pharmaceuticals Announces Phase 3 Trial Results for Ziihera
The company states: "Jazz Pharmaceuticals announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety profile of Ziihera (zanidatamab-hrii) in combination with chemotherapy, with and without the PD-1 inhibitor Tevimbra (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction, and esophagus. The manuscript builds on the late-breaking oral presentation of the HERIZON-GEA-01 trial results at the 2026 ASCO Gastrointestinal Cancers Symposium, where zanidatamab-containing combinations demonstrated unprecedented progression-free survival and overall survival outcomes in a global Phase 3 trial."
